Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The program priority for execution of this clinical trial changed prior to enrollment of the first patient. The study was not withdrawn due to any safety concerns.

Conditions

Acute Posthemorrhagic Anemia

Interventions

DRUG: BGE-117, 4mg
DIETARY_SUPPLEMENT: Ferrous Sulfate
OTHER: Matching Placebo
DRUG: BGE-117, 12mg

Sponsor

BioAge Labs, Inc.